Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

Alopecia jak Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (234) 5 alpha Reductase (7) Acyltransferase (1) Akt (1) Androgen Receptor (2) Antibiotic (4) Apoptosis (52) Arginase (1) Aurora Kinase (3) Autophagy (20) Bacterial (7) Bcr-Abl (4) Biochemical Assay Reagents (1) BMX Kinase (1) Btk (10) c-Kit (1) CDK (7) COX (3) Cytochrome P450 (1) Deubiquitinase (2) Dopamine Receptor (1) Drug Metabolite (2) EGFR (7) Endogenous Metabolite (5) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (2) FGFR (1) FLT3 (15) Fungal (6) GSK-3 (4) HBV (1) HCV (1) HDAC (4) IFNAR (3) IKK (4) Influenza Virus (2) Interleukin Related (6) Isotope-Labeled Compounds (5) Itk (1) JNK (2) Keap1-Nrf2 (4) LRRK2 (1) MEK (2) MicroRNA (1) Microtubule/Tubulin (1) Mitophagy (6) mTOR (1) nAChR (1) NF-κB (5) NO Synthase (2) p38 MAPK (3) Parasite (1) PI3K (1) PKC (1) Polo-like Kinase (PLK) (2) Prostaglandin Receptor (1) PROTACs (6) Reactive Oxygen Species (2) RET (3) Sirtuin (4) Src (2) STAT (33) STING (1) Syk (8) TGF-β Receptor (3) TNF Receptor (1) Toll-like Receptor (TLR) (1) Trk Receptor (1) Tyrosinase (1) VEGFR (3) Virus Protease (1)
By Research Areas:	Cancer (170) Cardiovascular Disease (5) Endocrinology (5) Infection (9) Inflammation/Immunology (128) Metabolic Disease (5) Neurological Disease (5)
Click Chemistry:	Alkynes (5)

292

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas

HY-111471A

JAK-IN-5 hydrochloride

JAK Inflammation/Immunology

JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
HY-111471

JAK-IN-5

JAK Inflammation/Immunology

JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.

JAK-IN-5 hydrochloride	JAK	Inflammation/Immunology
JAK-IN-5 hydrochloride is an inhibitor of *JAK* extracted from patent US20170121327A1, compound example 283.

JAK-IN-5	JAK	Inflammation/Immunology
JAK-IN-5 is an inhibitor of *JAK* extracted from patent US20170121327A1, compound example 283.

HY-157121

JAK-IN-34	JAK	Inflammation/Immunology
JAK-IN-34 (compound 11n) is a potent against of **JAKs with IC₅₀** values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively. JAK-IN-34 reduces joint swelling with good safety.****

HY-157011

JAK-IN-33

JAK Inflammation/Immunology

JAK-IN-33 (compound 3 (R)) is a JAK inhibitor.
HY-14986

JAK-IN-32

JAK Others

JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase.

JAK-IN-33	JAK	Inflammation/Immunology
JAK-IN-33 (compound 3 (R)) is a *JAK* inhibitor.

JAK-IN-32	JAK	Others
JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase.

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a *JAK* inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively.

HY-128450

JAK-STAT-IN-1	JAK STAT	Cancer Inflammation/Immunology
JAK-STAT-IN-1 (compound 1) is a selective *JAK-STAT* inhibitor. JAK-STAT-IN-1 can be used for the research of autoimmune disorder.

HY-149284

JAK/HDAC-IN-3

JAK HDAC Cancer

JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively.

JAK/HDAC-IN-3	JAK HDAC	Cancer
JAK/HDAC-IN-3 (13a) is a dual *JAK* and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively.

HY-144058

JAK-IN-18	JAK	Inflammation/Immunology
JAK-IN-18 is a potent inhibitor of *JAK. JAK*-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1).

HY-144057

JAK-IN-17	JAK	Inflammation/Immunology
JAK-IN-17 is a potent inhibitor of *JAK. JAK*-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1).

HY-148060

JAK-IN-21

JAK Cancer

JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively.

JAK-IN-21	JAK	Cancer
JAK-IN-21 (Example 4) is a selective and potent *JAK* inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively.

HY-125970

CRTh2 antagonist 2	Prostaglandin Receptor	Endocrinology
CRTh2 antagonist 2 is selective and potent CRTH2 antagonist extracted from patent US20140148470A1, compound Example 1, has an IC₅₀ of ≤10 nM. CRTh2 antagonist 2 can be used in research of androgenic alopecia.

HY-14250A

(Rac)-PF-998425	Androgen Receptor	Endocrinology
(Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist. (Rac)-PF-998425 has IC₅₀ values of 26 and 90 nM in the AR binding and cellular assays, respectively. (Rac)-PF-998425 has the potential for the research of the androgenetic alopecia.

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2.

HY-13827

JAK-IN-1 1 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-111750

JAK-IN-3

JAK Inflammation/Immunology

JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.

JAK-IN-3	JAK	Inflammation/Immunology
JAK-IN-3 (compound 22) is a potent *JAK* inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.

HY-139807

JAK-IN-14	JAK	Inflammation/Immunology
JAK-IN-14 is a potent and selective *JAK1* inhibitor, with an IC₅₀ of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).

HY-100759

JAK2-IN-4

JAK Cancer

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs).

HY-143444

JAK-IN-20	JAK	Inflammation/Immunology
JAK-IN-20 is a potent, pan and orally active *JAK* inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo.

HY-154994

JAK-IN-30	JAK	Inflammation/Immunology
JAK-IN-30 (compound 31) is a water-soluble *JAK* inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for *JAK2, JAK1, JAK3* and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED).

HY-153440

JAK-IN-25	JAK	Cancer
JAK-IN-25 (compound 19) is a potent *JAK* inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research.

HY-137756

JAK2-IN-6	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells.

HY-147975

JAK3-IN-12	JAK	Inflammation/Immunology
JAK3-IN-12 (compound 5k) is a highly potent *JAK3* inhibitor with IC₅₀ values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. JAK3-IN-12 can be used for researching rheumatoid arthritis.

HY-133747

JAK3-IN-9	JAK	Inflammation/Immunology
JAK3-IN-9 is an orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM. JAK3-IN-9 is highly selective to the *JAK3* signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research.

HY-100849

JAK 3i	JAK	Inflammation/Immunology
JAK3i is a highly selective *JAK3* inhibitor (IC₅₀: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for autoimmune disease research.

HY-19544

JAK3-IN-1	JAK	Cancer
JAK3-IN-1 is a potent, selective and orally active *JAK3* inhibitor with an IC₅₀ of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for *JAK3* than JAK1 (IC₅₀ of 896 nM) and JAK2 (IC₅₀ of 1050 nM).

HY-156706

JAK-IN-31	JAK	Cancer
JAK-IN-31 (Example 75) is a *JAK* inhibitor with IC₅₀ ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for *JAK1, JAK2, JAK3* and Tyk2 respectively. JAK-IN-31 can be used in cancer research.

HY-144440

JAK1-IN-9

JAK Cancer

JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more.

JAK1-IN-9	JAK	Cancer
JAK1-IN-9 (compound 23a) is a potent and selective *JAK1* inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more.

HY-116505

JAK1-IN-4	JAK	Cancer
JAK1-IN-4 is a potent and selective *JAK1* inhibitor, with IC₅₀s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC₅₀, 227 nM).

HY-149296

JAK1-IN-12	JAK	Inflammation/Immunology
JAK1-IN-12 is a selective inhibitor of *JAK1, with IC₅₀* of 0.0246 μM. And IC₅₀s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases.

HY-146727

JAK3-IN-11	JAK	Inflammation/Immunology
JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases.

HY-151262

JAK-IN-23	JAK STING NF-κB STAT	Inflammation/Immunology
JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC₅₀ values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC₅₀ values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD).

HY-153712

JAK-IN-28

JAK Cancer Inflammation/Immunology

JAK-IN-28 (Compound 111) is a JAK inhibitor. JAK-IN-28 can be used for research of cancer or inflammatory diseases.

JAK-IN-28	JAK	Cancer Inflammation/Immunology
JAK-IN-28 (Compound 111) is a *JAK* inhibitor. JAK-IN-28 can be used for research of cancer or inflammatory diseases.

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.

HY-150688

JAK3-IN-13	JNK	Cancer
JAK3-IN-13 is a potent, selective and orally active *JAK3* inhibitor with IC₅₀ values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity.

HY-155951

JAK3-IN-14	JAK	Cancer
JAK3-IN-14 (compound 1) is a potent *JAK3* inhibitor, with IC₅₀ values of 38 and 600 nM for *JAK3* and *JAK2, respectively. JAK3-IN-14 shows inhibitory of IL-4 and IL-3 induced TF-1 cell proliferation, with IC₅₀* values of 600 and 500 nM, respectively.

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Cancer Inflammation/Immunology
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for *JAK2* and *JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia.

HY-154969

JAK-IN-29

JAK Others

JAK-IN-29 (compound 3) is a potent JAK inhibitor.

JAK-IN-29	JAK	Others
JAK-IN-29 (compound 3) is a potent JAK inhibitor.

HY-10652

JAK-2/3-IN-1	JAK	Cancer Inflammation/Immunology
JAK-2/3-IN-1 is a potent *JAK-2* and *JAK-3* inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms.

HY-46262

JAK-IN-15

JAK Cancer

JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).

JAK-IN-15	JAK	Cancer
JAK-IN-15 is a *JAK* inhibitor. WO2016119700A1 (Compound 15).

HY-U00277

JAK-IN-10	JAK	Inflammation/Immunology
JAK-IN-10 is a *JAK* inhibitor. JAK-IN-10 can be used for the research of dry eye disorders. JAK-IN-10 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-126141

JAK/HDAC-IN-1	JAK HDAC	Cancer
JAK/HDAC-IN-1 is a potent *JAK2/HDAC* dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC₅₀s of 4 and 2 nM for JAK2 and HDAC, respectively.

HY-143718

JAK3/BTK-IN-3	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-3 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)

HY-143717

JAK3/BTK-IN-2	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-2 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)

HY-143720

JAK3/BTK-IN-5	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-5 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 35)

HY-143719

JAK3/BTK-IN-4	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-4 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-143716

JAK3/BTK-IN-1	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-1 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).

HY-153702

JAK-IN-27	JAK	Cancer
JAK-IN-27 (compound 1) is an orally active and potent *JAKS* family kinase inhibitor with IC₅₀s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively. JAK-IN-27 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=23.7 nM).

HY-149283

JAK/HDAC-IN-2	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine *JAK/HDAC* dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers.

HY-145029

SYK/JAK-IN-1

Syk JAK Cancer Inflammation/Immunology

SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC₅₀s of <5 nM for SYK and JAK2, respectively.
HY-101976

JAK3-IN-6

JAK Inflammation/Immunology

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.
HY-153566

JAK1-IN-10

JAK Cancer

JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, is a potent and selective JAK1 inhibitor.
HY-111749

JAK-IN-4

JAK Inflammation/Immunology

JAK-IN-4 is a proagent of a JAK inhibitor, effective in murine collagen induced arthritis model.
HY-U00390

JAK3-IN-7

JAK Cancer

JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC₅₀ of <0.01 μM.

HY-147754

JAK3/BTK-IN-6	Btk JAK	Inflammation/Immunology
JAK3/BTK-IN-6 (compound 14h) is a potent BTK and *JAK3* dual inhibitor, with IC₅₀ values of 0.6 and 0.4 nM, respectively. JAK3/BTK-IN-6 shows good metabolic stability in human liver microsome. JAK3/BTK-IN-6 can be used for hematological and immune diseases research.

HY-130247

JAK2/FLT3-IN-1 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.

HY-151256

JAK-2/3-IN-2

JAK Cancer

JAK-2/3-IN-2 (Compound 3h) is a JAK2 and JAK3 inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively.
HY-139423

JAK1-IN-8

JAK Cancer Inflammation/Immunology

JAK1-IN-8, a potent JAK1 inhibitor (IC₅₀<500 nM), compound 28, extracted from patent WO2016119700A1.

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs.

HY-143885

JAK1/TYK2-IN-3	JAK	Inflammation/Immunology
JAK1/TYK2-IN-3 is a potent, selective and orally active dual *TYK2/JAK1* inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to *JAK2* (IC₅₀=140 nM) and *JAK3* (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related *TYK2/JAK1*-regulated genes, as well as the formation of Th1, Th2, and Th17 cells.

HY-153701

JAK-IN-26	JAK	Cancer
JAK-IN-26 (compound 2) is an orally active *JAK* inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=17.2 nM).

HY-153050

JAK-IN-24	JAK	Cancer Inflammation/Immunology
JAK-IN-24 is a *JAK* inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM. JAK-IN-24 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130247A

JAK2/FLT3-IN-1 TFA 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.

HY-P1590

*Tyrosine Protein Kinase JAK* 2 (Phospho-Tyr8, 9)**	JAK	Cancer Inflammation/Immunology
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC₅₀ values of 9 and 157 nM for TYK2 and *JAK2, respectively. JAK*2/TYK2-IN-2 has anti-inflammatory activity.

HY-103347

M50054	Apoptosis	Inflammation/Immunology
M50054 is a potent inhibitor of apoptosis. M50054 inhibits Etoposide-induced caspase-3 activation of U937 cells with an IC₅₀ of 79 μg/mL. M50054 does not directly inhibit the enzymatic activity of caspase-3. M50054 can be used for the research anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia.

HY-U00318

JAK-IN-11	JAK	Inflammation/Immunology
JAK-IN-11 is a potent and selective *JAK* inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment. JAK-IN-11 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145336

JAK1/TYK2-IN-1

JAK Cancer

JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 (IC₅₀ = 29 and 41 nM respectively).
HY-131194

JAK2/STAT3-IN-1

Interleukin Related Cancer

JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity.

HY-156423

*Tubulin/JAK2-IN-1*	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells.

HY-144075

JAK-IN-19	JAK	Inflammation/Immunology
JAK-IN-19 is a potent *JAK* inhibitor (PBMC IFNγ pIC₅₀=7.2 and HLF Eotaxin pIC₅₀=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC₅₀=7.0, Aurora B pIC₅₀=5.8).

HY-50856S

Deuruxolitinib CTP-543; Ruxolitinib d₈; Deuterated Ruxolitinib	JAK	Inflammation/Immunology
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of *JAK1/JAK2*. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).

HY-102055

JAK2 JH2 Tracer

4 Publications Verification

JAK Others

JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a K_d of value 0.2 μM.

HY-14250

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal androgen receptor (AR) antagonist with an IC₅₀ of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research.

HY-13635A

Finasteride acetate MK-906 acetate	5 alpha Reductase	Cancer
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.

HY-13635

Finasteride 4 Publications Verification MK-906	5 alpha Reductase	Cancer
Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a K_d of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research.

HY-15480

NSC 42834 1 Publications Verification jak2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F and Jak*2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-18300A

Filgotinib maleate GLPG0634 maleate	JAK	Inflammation/Immunology
Filgotinib (maleate) is a selective and orally active *JAK1* inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM and 116 nM for JAK1, JAK2, JAK3 and TYK2, respectively. Filgotinib (maleate) can be used for rheumatoid arthritis (RA) and Crohn's disease research.

HY-126294

Londamocitinib AZD4604; jak1-IN-7	JAK	Inflammation/Immunology
Londamocitinib (AZD4604; JAK1-IN-7) is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.

HY-15508

JANEX-1 4 Publications Verification WHI-P131; jak3 inhibitor I	JAK	Cancer
JANEX-1 (WHI-P131) is a potent and specific *JAK3* inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC₅₀ of 78 μM), does not inhibit JAK1 and JAK2.

HY-156273

*HDAC/JAK/BRD4-IN-1*	JAK Epigenetic Reader Domain HDAC Apoptosis	Cancer
HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent *HDAC/JAK/BRD4* triple inhibitor. HDAC/JAK/BRD4-IN-1 inhibit cell growth and induces apoptosis in MDA-MB-231 cells, and shows anticancer activity in vivo.

HY-W062703S

(Rac)-Ruxolitinib-d9 (Rac)-INCB18424-d₉; Ruxotinib racemate-d₉	Isotope-Labeled Compounds JAK	Cancer
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor.

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

HY-14722A

NVP-BSK805 dihydrochloride	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

HY-14722

NVP-BSK805 1 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

HY-118528A

TP0427736 hydrochloride	TGF-β Receptor	Endocrinology
TP0427736 hydrochloride is a potent inhibitor of ALK5 kinase activity with an IC₅₀ of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC₅₀=836 nM). TP0427736 hydrochloride also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC₅₀ value of 8.68 nM. TP0427736 hydrochloride can be used for the research of androgenic alopecia (AGA).

HY-146066

*α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis.

HY-136336

Tofacitinib metabolite-1 1 Publications Verification	Drug Metabolite	Others
Tofacitinib metabolite-1 is a metabolite of Tofacitinib, a JAK inhibitor. Tofacitinib metabolite-1 can be used in the pharmacokinetics and metabolism studies of tofacitinib.

HY-15999A

Cerdulatinib hydrochloride 5 Publications Verification PRT062070 hydrochloride; PRT2070 hydrochloride	Syk JAK	Cancer
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and *JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK* and Tyk2, *JAK1*, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.

HY-115734

Phenylpyropene C S14-95	Acyltransferase	Inflammation/Immunology
Phenylpyropene C (S14-95), a *JAK/STAT* pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC₅₀=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of acyl-CoA, with an IC₅₀ of 16.0 μM.

HY-B0141AS1

Alpha-Estradiol-d2 Alfatradiol-d₂; Epiestradiol-d₂; Epiestrol-d₂	5 alpha Reductase Endogenous Metabolite	Metabolic Disease Cardiovascular Disease
Alpha-Estradiol-d₂ is the deuterium labeled Alpha-Estradiol. Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia[1].

HY-N2409

Delphinidin chloride	Apoptosis JAK STAT	Cancer Cardiovascular Disease
Delphinidin chloride, an anthocyanidin, is isolated from berries and red wine. Delphinidin chloride shows endothelium-dependent vasorelaxation. Delphinidin chloride also can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.

HY-W014605

Diphenylcyclopropenone Diphencyprone	Others	Inflammation/Immunology
Diphenylcyclopropenone (Diphencyprone) is a topical immunomodulatory agent that can be used for alopecia areata research.

HY-U00376

5α-reductase-IN-1	5 alpha Reductase	Metabolic Disease
5α-reductase-IN-1 is an inhibitor of 5α-reductase, used for the research of patterned alopecia in combination with minoxidil.

HY-B0141A

Alpha-Estradiol Alfatradiol; Epiestradiol; Epiestrol	5 alpha Reductase Endogenous Metabolite Bacterial	Inflammation/Immunology
Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia.

HY-13961

GLPG0634 analog

JAK Cancer

GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3.

HY-13635S

Finasteride-d9 MK-906-d₉	Isotope-Labeled Compounds 5 alpha Reductase	Cancer
Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

HY-10963

Momelotinib Mesylate CYT387 Mesylate	JAK Autophagy	Cancer
Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

HY-10961

Momelotinib 10+ Cited Publications CYT387	JAK Autophagy Apoptosis	Cancer
Momelotinib (CYT387) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.

HY-145696

SJ10542	PROTACs JAK	Cancer Inflammation/Immunology
SJ10542 is a potent and selective *JAK2/3* directing phenyl glutarimide (PG)-PROTAC with DC₅₀s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. SJ10542 utilizes a PG ligand as the cereblon (CRBN) recruiter.

HY-10962

Momelotinib sulfate 10+ Cited Publications CYT387 sulfate salt	JAK Autophagy Apoptosis	Cancer
Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC₅₀=155 nM).

HY-15315A

Baricitinib phosphate 30+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-12469

Decernotinib 3 Publications Verification VX-509; VRT-831509	JAK	Inflammation/Immunology
Decernotinib is a potent, orally active *JAK3* inhibitor, with K_is of 2.5, 11, 13 and 11 nM for *JAK3, JAK1, JAK*2, and TYK2, respectively.

HY-18300

Filgotinib 10+ Cited Publications GLPG0634	JAK	Cancer
Filgotinib (GLPG0634) is a selective and orally active *JAK1* inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-108417

Debio 0617B	STAT JAK Bcr-Abl	Cancer
Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34⁺ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors.

HY-13775

XL019 4 Publications Verification	JAK Apoptosis	Cancer
XL019 is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2.

HY-50856

Ruxolitinib Maximum Cited Publications 109 Publications Verification INCB18424	JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (INCB18424) is a potent and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Cancer Inflammation/Immunology
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for *JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects.

HY-50859

Ruxolitinib sulfate INCB018424 sulfate	JAK Autophagy	Cancer
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective *JAK1/2* inhibitor to enter the clinic with IC₅₀s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

HY-14435

Pyridone 6 5+ Cited Publications	JAK	Cancer
Pyridone 6 is a *pan-JAK* inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for *JAK2* and TYK2, 5 nM for *JAK3, and 15 nM for JAK1*, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-109053

Delgocitinib 1 Publications Verification JTE-052	JAK	Inflammation/Immunology
Delgocitinib (JTE-052) is a specific *JAK* inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

HY-18300S

Filgotinib-d4 GLPG0634-d₄	JAK	Cancer
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-16997

Itacitinib 5+ Cited Publications INCB039110	JAK	Cancer
Itacitinib (INCB039110) is an orally active and selective inhibitor of *JAK1* with an IC₅₀ of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.

HY-19568B

Peficitinib hydrochloride ASP015K hydrochloride; JNJ-54781532 hydrochloride	JAK	Inflammation/Immunology
Peficitinib (ASP015K) hydrochloride is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

HY-19568

Peficitinib 3 Publications Verification ASP015K; JNJ-54781532	JAK	Inflammation/Immunology
Peficitinib (ASP015K) is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

HY-19568A

Peficitinib hydrobromide ASP015K hydrobromide; JNJ-54781532 hydrobromide	JAK	Inflammation/Immunology
Peficitinib (ASP015K) hydrobromide is an orally active *JAK* inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

HY-B0141AS

Alpha-Estradiol-d3 Alfatradiol-d₃; Epiestradiol-d₃; Epiestrol-d₃	Endogenous Metabolite 5 alpha Reductase	Inflammation/Immunology
Alpha-Estradiol-d₃ is the deuterium labeled Alpha-Estradiol. Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia.

HY-101024

PF-06263276	JAK	Inflammation/Immunology
PF-06263276 (PF 6263276) is a potent and selective *pan-JAK* inhibitor, with IC₅₀s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively.

HY-P5253

Octapeptide-2	Reactive Oxygen Species	Metabolic Disease
Octapeptide-2 is a bioactive peptide with promotion of hair growth effect and has been reported used as a cosmetic ingredient.

HY-100895

SAR-20347

1 Publications Verification

JAK Cancer

SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC₅₀s of 0.6, 23, 26 and 41 nM, respectively.
HY-125083

Lys-D-Pro-Thr

Interleukin Related Metabolic Disease

Lys-D-Pro-Thr, an IL-1beta analogue, is a potent IL-1 inhibitor. Lys-D-Pro-Thr inhibits the protective effects of IL-1 beta.

HY-152080

TUL01101	JAK	Inflammation/Immunology
TUL01101 is a potent, selective and orally active *JAK1* inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis.

HY-15312

WP1066

15+ Cited Publications

STAT JAK Apoptosis Cancer

WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.

HY-19631B

Ilginatinib hydrochloride NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-108342

PF-00956980	JAK	Inflammation/Immunology
PF-00956980 is a reversible pan-JAK inhibitor with IC₅₀ values of 2.2, 23.1 and 59.9 μM for JAK1, JAK2 and JAK3, respectively. PF-00956980 can be used in the research of lung and skin inflammatory diseases.

HY-19631A

Ilginatinib NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631

Ilginatinib maleate NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-102046

FM-381 1 Publications Verification	JAK	Inflammation/Immunology
FM-381 is a potent covalent reversible inhibitor of *JAK3* targeting the unique Cys909. FM-381 has an IC₅₀ of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.

HY-10410

TG101209 4 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-15270

BMS-911543 2 Publications Verification	JAK	Cancer
BMS-911543 is a selective *JAK2* inhibitor, with IC₅₀s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC₅₀, 75, 360, 66 nM, respectively).

HY-10409

Fedratinib 25+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.

HY-10409A

Fedratinib hydrochloride hydrate 25+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.

HY-13577

Oclacitinib

1 Publications Verification

PF-03394197
JAK Inflammation/Immunology

Oclacitinib is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC₅₀=10 nM).

HY-50858

Ruxolitinib phosphate Maximum Cited Publications 109 Publications Verification INCB018424 phosphate	JAK Autophagy Mitophagy	Cancer
Ruxolitinib phosphate (INCB018424 phosphate) is a potent *JAK1/2* inhibitor with IC₅₀s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively.

HY-131014

FM-479	JAK	Inflammation/Immunology
FM-479 is the negative control of FM-381 (HY-102046) and has no activity on JAK3 or other kinases. FM-381 is a potent covalent reversible inhibitor of JAK3* targeting* the unique Cys909. FM-381 has an IC₅₀ of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.

HY-131140

BD750 1 Publications Verification	JAK STAT	Cancer Inflammation/Immunology
BD750, an effective immunosuppressant and a *JAK3/STAT5* inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC₅₀ values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.

HY-151259

TK4b	JAK	Cancer
TK4b is a Janus kinase (JAK) inhibitor with the IC₅₀ values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively. TK4b can be used in lymphoid-derived diseases and leukemia cancer research.

HY-151258

TK4g	JAK	Cancer
TK4g is a Janus kinase (JAK) inhibitor with the IC₅₀ values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research.

HY-107361

Golidocitinib AZD4205	JAK	Cancer
Golidocitinib (AZD4205) is a selective *JAK1* inhibitor, with an IC₅₀ of 73 nM, weakly inhibits JAK2 (IC₅₀>14.7 μM), and shows little inhibition on JAK3 (IC₅₀>30 μM).

HY-N1405

Cucurbitacin I 5+ Cited Publications Elatericin B; JSI-124; NSC-521777	STAT JAK	Cancer
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-40354

Tofacitinib 40+ Cited Publications Tasocitinib; CP-690550	JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-12000

AG490 90+ Cited Publications Tyrphostin AG490; Tyrphostin B42	EGFR STAT JAK Autophagy	Cancer
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

HY-113573

Protosappanin A PTA	JAK STAT	Inflammation/Immunology
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.

HY-123099

MS-1020	JAK	Cancer
MS-1020 is a potent and ATP-competitive *JAK3* inhibitor. MS-1020 inhibits JAK3/STAT signaling and induces apoptosis. MS-1020 promotes cell death. MS-1020 decreases the expression of tyrosine phosphorylated STAT3 levels. MS-1020 has the potential for the research of cancers harboring aberrant JAK3 signaling.

HY-16755

Solcitinib GSK-2586184; GLPG-0778	JAK	Inflammation/Immunology
Solcitinib is an orally active, competitive, potent, selective *JAK1* inhibitor, with an IC₅₀ of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.

HY-112391

SD-1029	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.

HY-103018

Gusacitinib ASN-002	JAK Syk	Cancer Inflammation/Immunology
Gusacitinib (ASN-002) is an orally active dual *SYK/JAK* kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, *JAK1, JAK2, JAK3* and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma.

HY-103018A

Gusacitinib hydrochloride ASN-002 hydrochloride	JAK Syk	Cancer Inflammation/Immunology
Gusacitinib (ASN-002) hydrochloride is an orally active dual *SYK/JAK* kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, *JAK1, JAK2, JAK3* and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma.

HY-112708

Brepocitinib 2 Publications Verification PF-06700841	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits *JAK2* and *JAK3* with IC₅₀s of 77 nM and 6.49 μM, respectively.

HY-13577A

Oclacitinib maleate 1 Publications Verification PF-03394197 maleate	JAK	Inflammation/Immunology
Oclacitinib maleate (PF-03394197 maleate) is a novel *JAK* inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting *JAK1* (IC₅₀=10 nM).

HY-18960

CHZ868

5 Publications Verification

JAK Cancer

CHZ868 is a type II JAK2 inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

HY-124858

SC99	STAT JAK Apoptosis	Cancer Cardiovascular Disease
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities.

HY-15315

Baricitinib 30+ Cited Publications LY3009104; INCB028050	JAK	Inflammation/Immunology
Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable *JAK1* and *JAK2* inhibitor with IC₅₀s of 5.9 nM and 5.7 nM, respectively.

HY-112708A

Brepocitinib P-Tosylate 2 Publications Verification PF-06700841 P-Tosylate	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits *JAK2* and *JAK3* with IC₅₀s of 77 nM and 6.49 μM, respectively.

HY-N1356

Reticuline	JAK STAT NF-κB Endogenous Metabolite	Inflammation/Immunology Cardiovascular Disease
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.

HY-11067

WHI-P97 2 Publications Verification	JAK	Inflammation/Immunology
WHI-P97 is a potent and selective *JAK-3* inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo.

HY-10193

AZD-1480

5+ Cited Publications

JAK Cancer

AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC₅₀s of 1.3 nM and <0.4 nM, respectively.

HY-18009

(Z)-LFM-A13 3 Publications Verification	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, *JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-N0635

Prim-O-glucosylcimifugin 2 Publications Verification	NO Synthase COX	Inflammation/Immunology
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-40354A

Tofacitinib citrate 40+ Cited Publications Tasocitinib citrate; CP-690550 citrate	JAK Apoptosis Bacterial Fungal Influenza Virus	Cancer Infection Inflammation/Immunology
Tofacitinib citrate is an orally available *JAK1/2/3* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-108264

TCS 21311 NIBR3049	JAK PKC GSK-3	Cancer
TCS 21311 (NIBR3049) is a potent, highly selective *JAK3* inhibitor with an IC₅₀ of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits PKCα, PKCθ, and GSK3β with IC₅₀s of 13, 68, and 3 nM, respectively.

HY-40354S

Tofacitinib-13C3 Tasocitinib-¹³C₃; CP-690550-¹³C₃	JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib-¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-115452

G5-7	JAK Apoptosis	Cancer
G5-7, an orally active and allosteric *JAK2* inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr¹⁰⁶⁸) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study.

HY-149647

HD-2a

Others Inflammation/Immunology

HA-2a can inhibit the JAK2/STAT3 pathway via downregulates circDcbld2 expression in RAW264.7 cells.

HY-15315S

Baricitinib-d5 LY3009104-d₅; INCB028050-d₅	JAK	Inflammation/Immunology
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3 LY3009104-d₃; INCB028050-d₃	JAK	Inflammation/Immunology
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-107595

SD-1008	JAK STAT Apoptosis	Cancer
SD-1008 is a potent *JAK* inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.

HY-107429

Abrocitinib 3 Publications Verification PF-04965842	JAK	Inflammation/Immunology
Abrocitinib (PF-04965842) is a potent, orally active and selective *JAK1* inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease.

HY-148785

Nimucitinib

JAK Others

Nimucitinib is a Janus kinase (JAK) inhibitor.

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research.

HY-19569

Upadacitinib 4 Publications Verification ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.

HY-15999

Cerdulatinib 5 Publications Verification PRT062070; PRT2070	JAK Syk	Cancer
Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC₅₀ of 0.5 nM. Cerdulatinib (PRT062070) also is a dual *JAK* and SYK inhibitor with IC₅₀s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.

HY-N2959

Brevilin A 1 Publications Verification	JAK STAT Apoptosis Autophagy	Cancer
Brevilin A is an orally active *STAT3/JAK* inhibitor (STAT3 IC₅₀= 10.6 µM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy.

HY-147330

SJ1008030	PROTACs JAK	Cancer
SJ1008030 (compound 8) is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 can be used for the research of leukemia.

HY-151385

VVD-118313	JAK STAT IFNAR Interleukin Related	Cancer
VVD-118313 (compound 5a) is a potent, selective *JAK1* inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer. VVD-118313 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-40354AS

Tofacitinib-d3 citrate Tasocitinib-d₃ citrate; CP-690550-d₃ citrate	Isotope-Labeled Compounds JAK Apoptosis Bacterial Fungal Influenza Virus	Cancer Infection Inflammation/Immunology
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-108419

WHI-P258	JNK	Cancer
WHI-P258, a quinazoline compound, binds to the active site of *JAK3* with an estimated K_i of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM.

HY-10411

AZ960

JAK Apoptosis Parasite Virus Protease Cancer

AZ960 is a potent and specific inhibitor of the JAK2 kinase with a K_i of 0.45 nM.
HY-148791

Pumecitinib

PG-011
JAK Cancer Inflammation/Immunology

Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity.
HY-139649

Ten01

JAK Others

Ten01 has 5.0 nM activity against JAK1 kinase.

HY-50856A

Ruxolitinib (S enantiomer) 4 Publications Verification S-Ruxolitinib; S-INCB18424	JAK	Cancer
Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib S enantiomer is a *JAK* inhibitor

HY-107594

Benzene hexabromide

JAK Cancer

Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation.
HY-112442

AZ-3

JAK Cancer

AZ-3 is a potent and selective JAK1 inhibitor with an IC₅₀ of 34 nM.

HY-126242S

Tyk2-IN-7	JAK	Inflammation/Immunology
Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-147330B

SJ1008030 formic	PROTACs JAK	Cancer
SJ1008030 (compound 8) formic is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 formic inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 formic can be used for the research of leukemia.

HY-147330A

SJ1008030 TFA	JAK PROTACs	Cancer
SJ1008030 (compound 8) TFA is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 TFA inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 TFA can be used for the research of leukemia.

HY-151385A

(R,R)-VVD-118313	STAT Interleukin Related IFNAR JAK	Cancer
(R,R)-VVD-118313 is the isomer of VVD-118313 (HY-151385). VVD-118313 is a selective *JAK1* inhibitor and blocks JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer. (R,R)-VVD-118313 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100544

FLLL32 4 Publications Verification	STAT JAK Apoptosis	Cancer
FLLL32, a synthetic analog of curcumina, is a *JAK2/STAT3* dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.

HY-109182

Lorpucitinib

JNJ-64251330
JAK Inflammation/Immunology

Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease.
HY-139837

GDC-4379

JAK Inflammation/Immunology

GDC-4379 is a JAK1 inhibitor that can be used for the research of asthma.

HY-107459

(E/Z)-AG490 (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42	EGFR STAT JAK	Cancer
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

HY-N1535

Ponicidin 2 Publications Verification Rubescensine B	Apoptosis	Cancer Inflammation/Immunology
Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens, and exhibits immunoregulatory, anti-inflammatory, anti-viral and anti-cancer activity. Ponicidin (Rubescensine B) induces apoptosis of gastric carcinoma cell, decreases the phosphorylation of JAK2 and STAT3, and shows no effect on protein levels of JAK2 and STAT3.

HY-18293

NSC 33994

JAK Autophagy Cancer

NSC 33994 (G6) is a selective JAK2 inhibitor, with an IC₅₀ of 60 nM.

HY-N2963

Broussonin E	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase	Inflammation/Immunology
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis.

HY-50514

AT9283 5 Publications Verification	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.

HY-15166B

(E/Z)-Zotiraciclib citrate

(E/Z)-TG02 citrate; (E/Z)-SB1317 citrate
CDK JAK FLT3 Cancer

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor.

HY-N1447

Ganoderic acid A 3 Publications Verification	Apoptosis Autophagy Endogenous Metabolite	Cancer
Ganoderic acid A can inhibit of the *JAK-STAT3* signaling pathway, also inhibit proliferation, viability, ROS.

HY-132819

Ilunocitinib

JAK Others

Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).

HY-10058

AT9283 lactic acid	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo.

HY-16379

Pacritinib 10+ Cited Publications SB1518	FLT3 JAK	Cancer
Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3^D835Y (IC₅₀=6 nM).

HY-W181102

NFAT Inhibitor-2	Others	Inflammation/Immunology Neurological Disease Cardiovascular Disease
NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).

HY-15343

CEP-33779

2 Publications Verification

JAK Cancer

CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC₅₀ of 1.8±0.6 nM.

HY-148798A

Rovadicitinib hydrochloride	JAK	Cancer Inflammation/Immunology
Rovadicitinib hydrochloride is a *JAK* inhibitor with an IC₅₀ value <20 nM. Rovadicitinib hydrochloride also exhibits anti-inflammatory activity.

HY-147742

Thi-DPPY	JAK	Inflammation/Immunology
Thi-DPPY (compound 8e) is a potent and orally active *JAK3* inhibitor with IC₅₀ values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF).

HY-144032

Tyk2-IN-9	JAK	Inflammation/Immunology
Tyk2-IN-9 (Compound 26) is a selective Tyk-2 inhibitor with IC₅₀s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease.

HY-100754

Ritlecitinib 5 Publications Verification PF-06651600	JAK	Inflammation/Immunology
Ritlecitinib (PF-06651600) is an orally active and selective *JAK3* inhibitor with an IC₅₀ of 33.1 nM.

HY-155807

DPP	Apoptosis JAK STAT	Cancer
DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand. DPP inhibit the JAK2-STAT3 pathway in breast cancer (BC) cells with antiproliferative activity, and activates caspase-3 and cleaved poly ADP-ribose polymerase to induces apoptosis. DPP promotes the maturation and antigen presentation of dendritic cells, and exhibits in vivo safety.

HY-144087

TYK2-IN-11	JAK	Inflammation/Immunology
TYK2-IN-11 (Compound 5B) is a selective Tyk-2 inhibitor with IC₅₀s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease.

HY-144031S

Tyk2-IN-8	Isotope-Labeled Compounds JAK	Inflammation/Immunology
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-109175

Fosifidancitinib	JAK	Inflammation/Immunology
Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.

HY-40354B

(3S,4R)-Tofacitinib

JAK Inflammation/Immunology

(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.
HY-148798

Rovadicitinib

JAK Cancer

Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC₅₀ value <20 nM. Rovadicitinib also exhibits anti-inflammatory activity.
HY-40354D

(3R,4S)-Tofacitinib

JAK Inflammation/Immunology

(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.

HY-152094

SRD5A1-IN-1	Others	Endocrinology
SRD5A1-IN-1 (Compound 4) is a competitive and covalent steroid 5α-reductase type 1 (SRD5A1) inhibitor with an IC₅₀ of 1.44 µM. SRD5A1-IN-1 modulates SRD5A1 function, leading to a lower level of dihydrotestosterone (DHT) production and SRD5A1 protein suppression.

HY-149257

HAT-SIL-TG-1&AT	JAK STAT	Cancer
HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits *JAK-STAT* signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions.

HY-N0678

Icaritin 1 Publications Verification Anhydroicaritin	Autophagy Apoptosis	Cancer
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis^[3.

HY-15166A

(E/Z)-Zotiraciclib hydrochloride 5 Publications Verification (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, *JAK2, and FLT3* inhibitor.

HY-16997A

Itacitinib adipate 5+ Cited Publications	JAK	Cancer
Itacitinib adipate is an orally bioavailable and selective *JAK1* inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.

HY-40354C

(3S,4S)-Tofacitinib

JAK Inflammation/Immunology

(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.
HY-109179

Itacnosertib

TP-0184
JAK TGF-β Receptor Cancer

Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871.

HY-W727879

Upadacitinib-15N,d2 ABT-494-¹⁵N,d₂	Isotope-Labeled Compounds	Others
Upadacitinib-¹⁵N,d₂ (ABT-494-¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib-¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib-¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib-¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research.

HY-12589

ZM39923 hydrochloride	JAK	Cancer Neurological Disease
ZM39923 hydrochloride is a *JAK3* inhibitor, with a pIC₅₀ of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (TGM2) with an IC₅₀ of 10 nM.

HY-12589A

ZM39923

JAK Cancer Neurological Disease

ZM39923 is a JAK3 inhibitor, with a pIC₅₀ of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC₅₀ of 10 nM.
HY-13895

WHI-P154

1 Publications Verification

EGFR JAK Apoptosis Cancer

WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.

HY-16379A

Pacritinib hydrochloride SB-1518 hydrochloride	JAK	Cancer
Pacritinib hydrochloride is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 V617F mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF).

HY-124727

ZT55	JAK Apoptosis	Cancer
ZT55 is an orally active and highly-selective *JAK2* inhibitor with an IC₅₀ value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia.

HY-156621

Lepzacitinib	JAK	Inflammation/Immunology
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases.

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	JAK Apoptosis	Cancer Neurological Disease
Dehydrocrenatidine, a natural alkaloid, is a specific *JAK* inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.

HY-109178

Ifidancitinib ATI-50002; ATI-502	JAK	Others
Ifidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.

HY-P1790

Axltide

JAK Metabolic Disease

Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases.

HY-145588A

Povorcitinib phosphate INCB54707 phosphate	JAK	Inflammation/Immunology
Povorcitinib phosphate is a potent and selective inhibitor of *JAK1*. Povorcitinib phosphate has the potential for the research of disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP).

HY-N1356A

(R)-Reticuline	Others	Inflammation/Immunology
(R)-Reticuline is an isomer of Reticuline (HY-N1356). Reticuline displays anti-inflammatory and cardiovascular effects through JAK2/STAT3 and NF-κB signaling pathways. Salutaridine is a key intermediate in morphine biosynthesis. Salutaridine can be converted from (R)-Reticuline in the poppy plant. The conversion system relies on membrane-bound cytochrome P-450 enzymes and also requires reducing cofactors NADPH, molecular oxygen, etc.

HY-109148

Izencitinib TD-1473; JNJ-8398	JAK	Inflammation/Immunology
Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted *JAK* inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis.

HY-156001

DUB-IN-7	Deubiquitinase	Cancer
DUB-IN-7 (compound 43) is a Deubiquitinating enzymes (DUBs) inhibitor. DUB-IN-7 can be used in the study of diseases mediated by dysregulated *JAK2* activity, such as leukemia.

HY-155808

STAT3-IN-18	COX Apoptosis JAK STAT	Cancer
STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells.

HY-118528

TP0427736	TGF-β Receptor	Cancer
TP0427736 is a selective inhibitor of ALK5 with an IC₅₀ of 2.72 nM. TP0427736 inhibits Smad2/3 phosphorylation in A549 cells. TP0427736 decreases the growth inhibition of human outer root sheath cells.

HY-132849

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation.

HY-13034

Gandotinib 3 Publications Verification LY2784544	JAK FLT3 FGFR VEGFR	Cancer
Gandotinib (LY2784544) is a potent *JAK2* inhibitor with IC₅₀ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC₅₀ of 4, 25, 32, 44, and 95 nM.

HY-145588

Povorcitinib INCB54707	JAK	Inflammation/Immunology
Povorcitinib is a potent and selective inhibitor of *JAK1*. Povorcitinib has the potential for the research of disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) (extracted from patent WO2021076124A1).

HY-148748

Butyzamide	JAK STAT p38 MAPK	Others
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay.

HY-15163

Zotiraciclib TG02; SB1317	JAK CDK FLT3	Cancer
Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, *JAK2* and FLT3 with IC₅₀ values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma.

HY-152227

PROTAC TYK2 degradation agent1	PROTACs JAK	Inflammation/Immunology
PROTAC TYK2 degradation agent1 is a potent and subtype-selective TYK2 degrader. PROTAC TYK2 degradation agent1 has TYK2 degradation activity with DC₅₀ value of 14 nM. PROTAC TYK2 degradation agent1 can be used for the research of autoimmune disease.

HY-W394903

GS-829845	JAK Drug Metabolite	Cancer
GS-829845 is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a *JAK1* preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life.

HY-N0705

Curculigoside 5 Publications Verification	JAK STAT NF-κB	Inflammation/Immunology Neurological Disease Cancer
Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the *JAK/STAT/NF-κB* signaling pathway.

HY-103438

BIBU1361	mTOR Akt Apoptosis	Cancer
BIBU1361 induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and *gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6*.

HY-13264

Degrasyn 5+ Cited Publications WP1130	Deubiquitinase Bcr-Abl Autophagy Apoptosis	Cancer
Degrasyn (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins Bcr-Abl and *JAK2*.

HY-155785

MTP	Reactive Oxygen Species Autophagy Apoptosis JAK	Cancer
MTP is a PKM2 inhibitor. MTP induces cancer cell apoptosis by modulating caspase-3 activation. MTP induces autophagy and increases ROS generation. MTP also inhibits *JAK2* signaling. MTP can be used for research of oral squamous cell carcinoma.

HY-147741

DPPY	JAK Btk EGFR	Cancer Inflammation/Immunology
DPPY (compound 6) is a potent PTK inhibitor with IC₅₀ values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF).

HY-N2515

Ginsenoside Rk1 1 Publications Verification	NF-κB PI3K JAK Apoptosis	Cancer Inflammation/Immunology
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of *Jak2/Stat3* signaling pathway and NF-κB. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway.

HY-109082

Cevidoplenib SKI-O-703	Syk	Inflammation/Immunology
Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively.

HY-100754B

(2R,5S)-Ritlecitinib (2R,5S)-PF-06651600	JAK	Inflammation/Immunology
(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective *JAK3* inhibitor (IC₅₀=144.8 nM) extracted from patent US20150158864A1, example 68.

HY-N0201

Atractylenolide I 2 Publications Verification	Toll-like Receptor (TLR) JAK STAT	Cancer
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated *JAK2* and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N0781

Linderalactone 1 Publications Verification	Apoptosis	Cancer
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 µM.

HY-15166

(E/Z)-Zotiraciclib 5 Publications Verification (E/Z)-TG02; (E/Z)-SB1317	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, *JAK2* and FLT3 with IC₅₀s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer.

HY-102084

LMT-28 5+ Cited Publications	Interleukin Related	Inflammation/Immunology
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.

HY-132601

Cobomarsen MRG-106	MicroRNA	Cancer
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including *JAK/STAT, MAPK/ERK* and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma.

HY-146672

ITK inhibitor 6	Itk	Cancer
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC₅₀s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities.

HY-116035

Nimbolide 1 Publications Verification	NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene derived from the leaves and flowers of neem (Azadirachta indica). Nimbolide induces apoptosis through inactivation of NF-κB. Nimbolide inhibits CDK4/CDK6 kinase activity. Nimbolide suppresses the NF-κB, Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways.

HY-151902

SJ988497	PROTACs JAK	Cancer
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL).

HY-N10623

5-epi-Arvestonate A	Tyrosinase	Cancer
5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells.

HY-110002

LFM-A13	Polo-like Kinase (PLK) Btk JAK	Cancer
LFM-A13 is a potent BTK, *JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

HY-80002

BMX-IN-1 4 Publications Verification BMX kinase inhibitor	Btk BMX Kinase	Cancer
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys⁴⁹⁶ in the BMX ATP binding domain with an IC₅₀ of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

HY-156466

QL-1200186	JAK	Inflammation/Immunology
QL-1200186 is anorally activeand selective inhibitor ofTYK2. Oral administration of QL-1200186, dose-dependently inhibitsinterferon-γ(IFNγ) production afterinterleukin-12(IL-12) challenge and significantly ameliorates skin lesions in psoriatic mice.

HY-18303

AMG-47a 2 Publications Verification	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is a potent and orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, with an IC₅₀ of 0.2 nM. AMG-47a also inhibits VEGF2, p38α, *Jak3* and MLR and IL-2 with IC₅₀s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively. AMG-47a has anti-inflammatory activity.

HY-132193

RET-IN-4	RET	Cancer
RET-IN-4 is a potent, selective and orally active RET inhibitor with IC₅₀s of 1.29 nM, 1.97 nM, and 0.99 nM for RET (WT), RET (V804M), and RET (M918T), respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC₅₀ of 4.4 nM) and FLT3 (IC₅₀ of 30.8 nM). RET-IN-4 has anticancer effects.

HY-50867

Lestaurtinib 2 Publications Verification CEP-701; KT-5555	JAK FLT3 Trk Receptor Apoptosis STAT	Cancer
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC₅₀s of 2, 25 and 0.9 nM for FLT3, TrkA and *JAK2, respectively. Lestaurtinib induces apoptosis* and cycle arrest, also can inhibit growth of tumor.

HY-112447

STAT3-IN-5	STAT	Cancer
STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC₅₀ value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer.

HY-153190A

W1131 TFA	STAT Ferroptosis	Cancer
W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY-90006). W1131 regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway.

HY-120214

TAS05567	Syk RET	Inflammation/Immunology
TAS05567 is a potent, highly selective, ATP-competitive and orally active Syk inhibitor with an IC₅₀ of 0.37 nM. In a panel of 192 kinases, TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR and RET with IC₅₀s of 10 nM, 4.8 nM, 600 nM and 29 nM, respectively). TAS05567 can be used for humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases.

HY-150538

STAT3-IN-12	STAT Apoptosis	Cancer
STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma.

HY-W127408

Tripalmitolein	Biochemical Assay Reagents	Others
1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.

HY-153190

W1131	STAT Ferroptosis	Cancer
W1131 is a potent STAT3 inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including *IL6-JAK-STAT3* pathway and ferroptosis pathway.

HY-111553

TAS0728	EGFR	Cancer
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC₅₀ of 13 nM. TAS0728 also shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for *BMX、HER4、BLK、EGFR、JAK3、SLK* and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2HER3, and downstream effectors.

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, *JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin.

HY-18949

JI6	FLT3 JAK c-Kit	Cancer
JI6 is a potent, selective and orally active FLT3 inhibitor, with IC₅₀s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits *JAK3* and c-Kit, with IC₅₀s of ∼250 and ∼500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia.

HY-150096

Zasocitinib

NDI-034858; TAK-279
JAK Inflammation/Immunology

Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant K_d of <200 pM.

HY-W063968

RO8191 4 Publications Verification CDM-3008; RO4948191	IFNAR JAK STAT HCV HBV	Infection
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and *JAK/STAT* phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC₅₀ of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity.

HY-120920

UNC9995	Dopamine Receptor	Inflammation/Immunology
UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing β-arrestin2-NLRP3 interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by *JAK/STAT3*. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions.

HY-149007

STAT3-IN-11	STAT Apoptosis	Cancer
STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers.

HY-15504A

RGB-286638 free base 2 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-131968

BMS-986202	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium.

HY-15504

RGB-286638 2 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-16561

Resveratrol 65+ Cited Publications trans-Resveratrol; SRT501	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.

HY-16561R

Resveratrol (Standard) 65+ Cited Publications trans-Resveratrol (Standard); SRT501 (Standard)	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.

HY-16561S1

Resveratrol-13C6 trans-Resveratrol-¹³C₆; SRT501-¹³C₆	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol-¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S

Resveratrol-d4 trans-Resveratrol-d₄; SRT501-d₄	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-147826

EGFR-IN-60	EGFR Apoptosis	Cancer
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR^WT, EGFR^T790M, EGFR^L858R and *JAK3* with IC₅₀s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR^T790M mutation (IC₅₀=1.32 µM) over A431 cells overexpressing EGFR^WT (IC₅₀=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio.

HY-155178

Antiproliferative agent-34	EGFR	Cancer
Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC₅₀ of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC₅₀ of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC₅₀ values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC₅₀ values < 10 nM) under hypoxic condition.

Cat. No.	Product Name

Cat. No.	Product Name	Type

Cat. No.	Product Name	Type

Cat. No.	Product Name	Target	Research Area

Cat. No.	Product Name	Target	Category

Species:	Human (4)
Tag:	His (4)
Source:	P. pastoris (2) E. coli (2)

Cat. No.	Product Name	Species	Source

Cat. No.	Product Name

Cat. No.	Product Name	Application	Reactivity

Cat. No.	Product Name		Classification

Alopecia jak Inhibitors

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products